EUVIMEDEUVIMED entdecken
Open Access

Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022

M Cecilia Lansang iD, Lucia C Petito, Emma Hegermiller, Indhumathy Chelliah, Ryan M Carnahan, Marie E McDonnell, Andrea DeVries, Elisa Priest, Vincent Willey, Vinit Nair, Satyender Goel, Alan F Kaul und 2 weitere

Diabetes Obesity and Cardiometabolic CARE · 01.07.2026 · 1 (4) · 638-648

DOI: 10.2337/doc26-0027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Obesity and Cardiometabolic CARE, online erschienen am 13.07.2026. Verfasst von M Cecilia Lansang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: PCORI.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To compare nationwide prescription trends in medications (dipeptidyl peptidase 4 inhibitors [DPP-4i], glucagon-like peptide 1 receptor agonists [GLP-1 RAs], sodium–glucose cotransporter 2 inhibitors [SGLT2i], or sulfonylureas [SUs]) after treatment with metformin in patients with type 2 diabetes (T2D) at high versus moderate cardiovascular risk by key sociodemographic and health characteristics. RESEARCH DESIGN AND METHODS Electronic health records and insurance claims from 2014 to 2022 from 10 health systems and two insurance plans from different U.S. regions were evaluated. Risk-stratified multinomial log-linear models were used to model trends in prescribing patterns, adjusted for sociodemographic variables. RESULTS A total of 104,474 patients were included (28% at high and 72% at moderate cardiovascular risk). Among those at high cardiovascular risk, DPP-4i (2014 24.0%; 2022 11.0%) and SU (66.4%; 35.7%) prescriptions declined, whereas GLP-1 RA (4.4%; 20.5%) and SGLT2i (5.2%; 32.8%) prescriptions increased. Among those at moderate cardiovascular risk, DPP-4i (23.7%; 11.7%) and SU (63.7%; 31.5%) prescriptions declined, whereas GLP-1 RA (5.7%; 30.0%) and SGLT2i (6.9%; 26.8%) prescriptions increased. Annual increases differed by high versus moderate cardiovascular risk for GLP-1 RAs (+2.5% vs. +3.6%/year; P < 0.001) and SGLT2i (+4.0% vs. +3.0%/year; P < 0.001). Greater annual increases in GLP-1 RA prescriptions occurred in women, those aged <65 years, and those with class 2 or 3 obesity, and greater annual increases in SGLT2i prescriptions were seen in men, those aged ≥65 years, and those without class 2 or 3 obesity (all P < 0.01). Greater increases in SGLT2i prescriptions occurred among Black patients, and greater increases in GLP-1 RA prescriptions occurred among those of Hispanic ethnicity at moderate cardiovascular risk. CONCLUSIONS Prescribing patterns for second-line T2D therapies in those at moderate cardiovascular risk are approaching guideline recommendations for those at high risk. Some trends are potentially clinically explainable, whereas certain racial/ethnic differences may warrant exploration.

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH.
  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH.
  • Feinberg School of Medicine, Northwestern University, Chicago, IL.
  • Indus Consulting, Inc., Chicago, IL.
  • College of Public Health, University of Iowa, Iowa City, IA.
  • Greater Plains Collaborative, Iowa City, IA.

ORCID-Profile: M Cecilia Lansang, Alexander Turchin

Förderung

  • PCORI

Zitieren

APA

Lansang, M. C., Petito, L. C., Hegermiller, E., Chelliah, I., Carnahan, R. M., McDonnell, M. E., DeVries, A., Priest, E., Willey, V., Nair, V., Goel, S., Kaul, A. F., Turchin, A., & BESTMED Research Group* (2026). Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022. Diabetes Obesity and Cardiometabolic CARE, 1(4), 638-648. https://doi.org/10.2337/doc26-0027

Vancouver

Lansang MC, Petito LC, Hegermiller E, Chelliah I, Carnahan RM, McDonnell ME, et al. Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022. Diabetes Obesity and Cardiometabolic CARE. 2026;1(4):638-648. doi:10.2337/doc26-0027

BibTeX
@article{Lansang2026,
  author = {Lansang, M Cecilia and Petito, Lucia C and Hegermiller, Emma and Chelliah, Indhumathy and Carnahan, Ryan M and McDonnell, Marie E and DeVries, Andrea and Priest, Elisa and Willey, Vincent and Nair, Vinit and Goel, Satyender and Kaul, Alan F and Turchin, Alexander and BESTMED Research Group*, BESTMED Research Group*},
  title = {Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022},
  journal = {Diabetes Obesity and Cardiometabolic CARE},
  year = {2026},
  volume = {1},
  number = {4},
  pages = {638--648},
  doi = {10.2337/doc26-0027}
}
Kostenlos starten →